SS-31 (Elamipretide): the mitochondria-targeted peptide research profile
SS-31 (elamipretide, branded as Forzinity in its approved form) is one of the most mechanistically specific compounds in the peptide research space. Where most research peptides act on receptors at the cell surface or in the cytoplasm, SS-31 is designed to penetrate the inner mitochondrial membrane and bind cardiolipin — a phospholipid found exclusively in that membrane and nowhere else in the cell. The cardiolipin binding mechanism gives SS-31 a precision that few compounds share: it targets the exact site where mitochondrial energy production fails under conditions of oxidative stress and aging. In September 2025, SS-31 as elamipretide received FDA accelerated approval for Barth syndrome — the first mitochondria-targeted therapeutic to reach regulatory approval in the United States — validating the cardiolipin mechanism that has been the subject of two decades of research.
Cardiolipin: the structural anchor SS-31 targets
Cardiolipin is a uniquely structured phospholipid with four fatty acid chains — double the number found in other membrane phospholipids — that is synthesised exclusively in the inner mitochondrial membrane (IMM). Its structure makes it ideally suited to serve as the physical scaffold that organises the electron transport chain (ETC) complexes into “supercomplexes” — higher-order assemblies of ETC complexes I, III, and IV that dramatically increase the efficiency of electron transfer and ATP synthesis. When cardiolipin is damaged by reactive oxygen species, peroxidised, or reduced in quantity (as occurs with aging and in conditions like Barth syndrome), these supercomplexes disassemble, electron transfer becomes less efficient, and electrons leak from the chain to form superoxide — accelerating the oxidative damage cycle.
This cardiolipin degradation cycle is a central mechanism in the energy production decline associated with aging: mitochondria in aged tissue produce less ATP per unit of substrate consumed and generate more ROS in the process. SS-31 interrupts this cycle at its source. The peptide’s alternating aromatic and cationic residues (D-Arg-Dmt-Lys-Phe-NH2 in its original Szeto-Schiller sequence) allow it to accumulate at the IMM surface through electrostatic attraction and then bind cardiolipin via aromatic interaction. This positioning between cardiolipin and cytochrome c stabilises the electron carrier in its electron-transfer competent configuration and reduces cardiolipin peroxidation — restoring supercomplex assembly and ETC efficiency.
The FDA approval: Barth syndrome and what it validates
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the Tafazzin gene (TAZ), which encodes the enzyme responsible for remodelling cardiolipin into its mature, functional form. Without functional tafazzin, cardiolipin remains in immature, aberrant forms that cannot support supercomplex assembly. The result is a severe cardiomyopathy, skeletal muscle weakness, neutropenia, and growth retardation that is fatal in a significant proportion of affected males before adulthood. In September 2025, the FDA granted accelerated approval to elamipretide (SS-31, branded Forzinity by Stealth BioTherapeutics) for the treatment of Barth syndrome based on cardiac and skeletal muscle function improvement in clinical trials.
The clinical significance of this approval for the broader SS-31 research context is that it provides regulatory validation for the cardiolipin mechanism in a human disease defined by cardiolipin dysfunction. The Barth syndrome approval is not an efficacy approval for aging or general mitochondrial decline — accelerated approval is based on a surrogate endpoint likely to predict clinical benefit, and post-marketing confirmatory trials are required. But it establishes that SS-31 reaches its proposed target and produces measurable physiological changes in the direction predicted by the cardiolipin mechanism — a level of human validation that almost no other research peptide can claim.
Heart failure and skeletal muscle research
Beyond Barth syndrome, the most substantial SS-31 clinical dataset comes from heart failure research. The TAZPOWER trial (Szeto et al., reported 2021) examined SS-31 in heart failure with preserved ejection fraction (HFpEF) — a condition in which the heart is stiff and fails to relax normally, with mitochondrial dysfunction implicated in the myocardial energy deficit. HFpEF affects approximately 50% of heart failure patients and has no approved disease-modifying therapy as of 2026. The TAZPOWER trial demonstrated that SS-31 treatment improved exercise capacity (6-minute walk distance) compared to placebo, with the improvement correlating with improvements in measures of mitochondrial membrane potential in endomyocardial biopsies. This mechanistic correlation between clinical outcome and mitochondrial function is the kind of target engagement evidence that makes the preclinical-to-clinical translation case credible.
Skeletal muscle research is another active area. Siegel et al. (2013, FASEB J) demonstrated in aged mice that a single subcutaneous injection of SS-31 rapidly improved mitochondrial membrane potential and restored muscle fibre contractile force to levels comparable to young animals — effects that persisted for days after a single dose. The proposed mechanism is that SS-31’s cardiolipin stabilisation rapidly restores ETC supercomplex assembly, producing an energy repletion that improves contractile performance without any change in mitochondrial number or muscle fibre composition. This is a fundamentally different approach to muscle aging research than anabolic peptides: SS-31 addresses energy production efficiency rather than protein synthesis rate.
Aging and longevity research context
SS-31’s relevance to longevity research stems from the central role of mitochondrial dysfunction in the biology of aging. The mitochondrial free radical theory of aging — originally proposed by Harman in 1972 and substantially refined since — posits that cumulative mitochondrial ROS damage to mtDNA, proteins, and lipids (including cardiolipin) drives the progressive cellular dysfunction characteristic of aging. SS-31 does not address mtDNA mutations or protein carbonylation, but by stabilising cardiolipin and reducing the ETC electron leak that generates most mitochondrial ROS under normal physiological conditions, it addresses the upstream driver of a substantial portion of mitochondrial oxidative damage.
In the Mito Stack context — the combination of SS-31, MOTS-c, and NAD+ precursors that we cover in our Mito Stack guide — SS-31 is the membrane integrity layer. MOTS-c drives AMPK activation and mitochondrial biogenesis signalling; NAD+ precursors supply the substrate for sirtuin and PARP enzyme function; SS-31 stabilises the physical structure that allows the ETC to operate efficiently regardless of substrate and enzyme availability. The three mechanisms are genuinely non-overlapping, which is why the stack logic holds up to mechanistic scrutiny in a way that many multi-compound research protocols do not. The individual SS-31 database entry and dose calculator are in our SS-31 peptide profile.
Research dosing reference
| Parameter | Value |
|---|---|
| Approved dose (Barth syndrome) | 40 mg subcutaneous daily (Forzinity prescribing information) |
| Research dose range (preclinical/early human) | 1–40 mg subcutaneous or IV |
| Route | Subcutaneous (approved form); IV infusion (clinical trials) |
| Frequency | Daily (approved protocol); research protocols vary |
| Cycle (research context) | 3–4 week cycles with rest periods standard in research |
| Half-life | ~2–4 hours (subcutaneous) |
| Storage | Reconstituted: refrigerated 2–8°C; use within 30 days |
What the evidence establishes and what it does not
SS-31 has the strongest human clinical evidence base of any peptide in the mitochondrial category. The FDA approval for Barth syndrome provides target validation in a human disease. The HFpEF data provides clinical outcome data in a common condition. The preclinical aging data provides mechanistic plausibility for the longevity applications that drive community interest. What the evidence does not yet establish is efficacy in healthy aging in a controlled human randomised trial — the kind of study that would confirm whether the improvements in mitochondrial function observed in disease states translate to measurable outcomes in otherwise healthy individuals with age-related mitochondrial decline. That research is ongoing. The mechanistic case is strong enough that SS-31 remains one of the most scientifically credible compounds in the longevity peptide category, even before that confirmatory trial data is available.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. Elamipretide (Forzinity) is FDA-approved for Barth syndrome only. This is not medical advice.
Sources
- Szeto HH. (2011). Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. PubMed
- Siegel MP, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. PubMed
- Daubert MA, et al. (2017). Novel mitochondria-targeting peptide in heart failure with preserved ejection fraction: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. PubMed
- Chatfield KC, et al. (2019). Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. PubMed
- FDA — Forzinity (elamipretide) accelerated approval for Barth syndrome (September 2025): fda.gov